Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Provincial Landscape
Snapshot: 2026-09-04
Jilin Multiple Myeloma Active Trials & Centers
As of 2026-09-04, there are 17 active clinical trials for multiple myeloma hosted across 4 tertiary medical centers in Jilin (including The First Hospital of Jilin University, Siping Central People's Hospital, China-Japan Union Hospital of Jilin University, etc.).
Active Trials
17
Hospitals
4
Therapies
CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents
Participating Medical Centers (4)
The First Hospital of Jilin UniversitySiping Central People's HospitalChina-Japan Union Hospital of Jilin UniversityJilin Provincial Cancer Hospital
Active Studies in Jilin (17)
Population synthesized by CMDNShowing 1 published English records of 17 registry trials.
Phase IICTR20261752
RecruitingA Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Population: Multiple myeloma
Target: Trispecific antibody targeting BCMA, CD3, and GPRC5D
Study Sites: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Heze Municipal Hospital 等 39 家中心